Article

QLT, Wilmer Eye Institute sign R&D agreement

Vancouver, British Columbia-QLT Inc. has entered into a 2-year research collaboration and option agreement with investigators at The Wilmer Eye Institute at Johns Hopkins University, Baltimore, to study and develop potential treatments for dry age-related macular degeneration (AMD).

Vancouver, British Columbia-QLT Inc. has entered into a 2-year research collaboration and option agreement with investigators at The Wilmer Eye Institute at Johns Hopkins University, Baltimore, to study and develop potential treatments for dry age-related macular degeneration (AMD).

Under the terms of the agreement, QLT will provide Johns Hopkins with $1.45 million in funding over 2 years to support research by James T. Handa, MD, and Peter L. Gehlbach, MD, PhD, of the institute. Dr. Handa is the associate chief of the retina division and vice chairman for quality assurance, and Dr. Gehlbach is an assistant professor.

The agreement provides QLT with the first option to negotiate an exclusive license to patented products resulting from the research. If QLT exercises this option, then the company will pay the university certain financial milestones and royalties.

“It is an honor to have the opportunity to collaborate with The Wilmer Eye Institute, which is one of the world’s most prestigious academic ophthalmic institutions,” said Bob Butchofsky, president and chief executive officer of QLT. “This agreement further demonstrates QLT’s focus and commitment to achieving our goal of developing new treatments for ocular diseases.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.